Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA

THOUSAND OAKS, Calif. and BRUSSELS, July 21, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news